Study shows Lucid's EsoGuard test detects esophageal precancer in at-risk patients without symptoms. Read more here.

Lucid Diagnostics shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, condu ...

Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced ...

Lucid Diagnostics Inc.’s LUCD share price has surged by 5.96%, which has investors questioning if this is right time to sell.

The firm raised the money last week in a public offering of 14,375,000 common shares, and it will use the money for working capital and general corporate purposes.

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.

Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and ...

NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...